Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
| ▸ | RAB9A | P51151 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442005 | 1.00 | CA2 (0.74) | CA2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4366751 | 0.91 | CA2 (0.67) | CA2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL27659000 | 0.91 | CA2 (0.67) | CA2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL4364568 | 0.90 | CA2 (0.65) | CA2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL27679115 | 0.90 | CA2 (0.65) | CA2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL11921824 | 0.88 | CA2 (0.77) | CA2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL6938746 | 0.88 | CA2 (0.59) | CA2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL6850655 | 0.88 | CA2 (0.59) | CA2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL8588574 | 0.88 | CA2 (0.59) | CA2NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL7971423 | 0.88 | CA2 (0.59) | CA2NPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112321678-A | NMDA receptor modulators and prodrugs, salts and uses thereof | 诺雷克斯股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-10590167-B2 | NMDA receptor modulators and prodrugs, salts, and uses thereof | NAUREX, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3564256-A1 | NMDA RECEPTOR MODULATORS | Naurex Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20180127466-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127466-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9745342-B2 | NMDA receptor modulators and prodrugs, salts, and uses thereof | NAUREX, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745342-B2 | NMDA receptor modulators and prodrugs, salts, and uses thereof | NAUREX, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745342-B2 | NMDA receptor modulators and prodrugs, salts, and uses thereof | NAUREX, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-3062810-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | Naurex Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160244485-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX INC (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244485-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX INC (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244485-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX INC (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2015065891-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015065891-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | NAUREX, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-0628559-B1 | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF LILLY GMBH (DE) | 2002-04-03 | — | — | EP | disclosed |
| US-5602136-A | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5602137-A | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5571813-A | Fused pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1996-11-05 | — | — | US | disclosed |
| EP-0628559-A1 | Pyrimidine compounds and their use as pharmaceuticals | Beiersdorf-Lilly GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590167-B2 | NMDA receptor modulators and prodrugs, salts, and uses thereof | GRIN1, GRIN3A, GRIN2A | CA2 1859/4885NPC1 968/4885RAB9A 2193/4885 |
| US-20180127466-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | GRIN1, GRIN3A, GRIN2A | CA2 1859/4885NPC1 968/4885RAB9A 2193/4885 |
| US-20160244485-A1 | NMDA RECEPTOR MODULATORS AND PRODRUGS, SALTS, AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CA2 3439/4885NPC1 776/4885RAB9A 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.